• portrait of Henry A. Dunn
  • Assistant professor

    Max Rady College of Medicine
    Department of Pharmacology and Therapeutics
    University of Manitoba

    Room R4052 – 351 Tache Avenue
    St. Boniface Hospital Albrechtsen Research Centre
    Winnipeg, Manitoba R2H 2A6
    Office: 204-258-1357
    Lab: 204-235-3949 

Research summary

Dr. Henry A. Dunn’s research aims to elucidate the molecular mechanisms underlying neurodevelopmental and neuropsychiatric disease with the goal of facilitating the development of novel therapeutic strategies for a myriad of neurological conditions, including autism spectrum disorder (ASD), anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and epilepsy.

With a prominent focus and expertise on G protein-coupled receptors (GPCRs) and their associated signalling pathways – the pharmaceutical target of over 35% of FDA-approved drugs – Dr. Dunn’s lab utilizes multidisciplinary approaches spanning molecular mechanisms to rodent models, including: molecular pharmacology, biochemistry, cellular & molecular neurobiology, bioinformatics and behavioural neuroscience.

  • Research themes

    • Biochemistry
    • Molecular pharmacology
    • Cellular and molecular neurobiology
    • Behavioural neuroscience
    • Bioinformatics
  • Research interests

    • Neuropsychiatric disease
    • Neurodevelopmental disease
    • Neurodegenerative disease
  • Keywords

    G protein-coupled receptors (GPCRs)
    Synaptic adhesion molecules
    Trans-synaptic interactions
    Intracellular signalling

  • Research affiliations

    • Principal investigator, St. Boniface Hospital Albrechtsen Research Centre


Dr. Henry A. Dunn is an assistant professor in the Department of Pharmacology and Therapeutics at the University of Manitoba, and a principal investigator at St. Boniface Hospital Albrechtsen Research Centre where he leads the Molecular Pharmacology and Neuropsychiatric Disease Lab.

Dr. Dunn is best known for his work on G protein-coupled receptors (GPCRs): particularly, delineating molecular mechanisms of stress-induced anxiety and depression, and illuminating a novel trans-synaptic pharmacological regulation mechanism with relevance to attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and epilepsy.

These seminal studies have led to a keen interest in the interplay between synaptic adhesion molecules and synaptic GPCRs, including: (1) how these relationships are utilized in synaptic connectivity, neurotransmission and intracellular signalling, and (2) how these interfaces can be exploited for novel drug design in neuropsychiatric disease.

Education and training

  • Postdoctoral Fellowship (Neuroscience), The Scripps Research Institute (2022)
  • Postdoctoral Fellowship (Cellular & Molecular Medicine), University of Ottawa (2016)
  • PhD (Physiology), University of Western Ontario (2014)
  • BMSc (Medical Science and Physiology), University of Western Ontario (2008)



  • Canadian Institute of Health Research (CIHR) Postdoctoral Fellowship (2016-2020)
  • Jonathan and Joshua Memorial Graduate Scholarship: Mental Health Research (2013-2014)
  • Jonathan and Joshua Memorial Graduate Scholarship: Mental Health Research (2012-2013)
  • Canadian Institute of Health Research (CIHR) Strategic Training Fellowship (2009-2011)

Contact us

Pharmacology and Therapeutics
Max Rady College of Medicine
A205 Chown Bldg., 753 McDermot Avenue
University of Manitoba (Bannatyne campus)
Winnipeg, MB R3E 0T6 Canada